Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  1/23/2018
Midwest Immunology
mi
from
Plymouth, MN
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 1/23/2018
Midwest Immunology
mi
from
Plymouth, MN
Click here to add this to my saved trials
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  1/23/2018
Midlands Pediatrics PC
mi
from
Papillion, NE
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 1/23/2018
Midlands Pediatrics PC
mi
from
Papillion, NE
Click here to add this to my saved trials
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  1/23/2018
Winthrop Allergy and Immunology
mi
from
Mineola, NY
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 1/23/2018
Winthrop Allergy and Immunology
mi
from
Mineola, NY
Click here to add this to my saved trials
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  1/23/2018
Oklahoma Institute of Allergy & Asthma Clinical Research
mi
from
Oklahoma City, OK
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 1/23/2018
Oklahoma Institute of Allergy & Asthma Clinical Research
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  1/23/2018
Allergy and Clinical Immunology Associates
mi
from
Pittsburgh, PA
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 1/23/2018
Allergy and Clinical Immunology Associates
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  1/23/2018
Allergy, Asthma & Immunology Clinic, P.A.
mi
from
Irving, TX
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 1/23/2018
Allergy, Asthma & Immunology Clinic, P.A.
mi
from
Irving, TX
Click here to add this to my saved trials
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  1/23/2018
IMMUNOe International Research Centers
mi
from
Thornton, CO
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 1/23/2018
IMMUNOe International Research Centers
mi
from
Thornton, CO
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
UCLA CARE Center CRS (601)
mi
from
Los Angeles, CA
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
UCLA CARE Center CRS (601)
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
University of Colorado Hospital CRS (6101)
mi
from
Aurora, CO
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
University of Colorado Hospital CRS (6101)
mi
from
Aurora, CO
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
Massachusetts General Hospital ACTG CRS (101)
mi
from
Boston, MA
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
Massachusetts General Hospital ACTG CRS (101)
mi
from
Boston, MA
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
University of Rochester Adult HIV Therapeutic Strategies Network CRS (31787)
mi
from
Rochester, NY
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
University of Rochester Adult HIV Therapeutic Strategies Network CRS (31787)
mi
from
Rochester, NY
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
Unc Aids Crs
mi
from
Chapel Hill, NC
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
Unc Aids Crs
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
Univ. of Cincinnati CRS (2401)
mi
from
Cincinnati, OH
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
Univ. of Cincinnati CRS (2401)
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
Case CRS (2501)
mi
from
Cleveland, OH
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
Case CRS (2501)
mi
from
Cleveland, OH
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
Vanderbilt Therapeutics CRS (3652)
mi
from
Nashville, TN
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
Vanderbilt Therapeutics CRS (3652)
mi
from
Nashville, TN
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
Houston AIDS Research Team CRS (31473)
mi
from
Houston, TX
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
Houston AIDS Research Team CRS (31473)
mi
from
Houston, TX
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
Puerto Rico-AIDS CRS (5401)
mi
from
San Juan,
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
Puerto Rico-AIDS CRS (5401)
mi
from
San Juan,
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
University of Washington AIDS CRS (1401)
mi
from
Seattle, WA
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
University of Washington AIDS CRS (1401)
mi
from
Seattle, WA
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
Washington U CRS (2101)
mi
from
Saint Louis, MO
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
Washington U CRS (2101)
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously
Phase 1/2 Determination of the Dose of Recominant Human Hyaluronidase (rHuPH20) Required Enabling Up to 600 mg/kg Bodyweight of IGIV, 10% to be Administered Subcutaneously in a Single Infusion Site in Subjects With Primary Immunodeficiency (PID)
Status: Enrolling
Updated:  1/23/2018
First Allergy and Clinical Research Center
mi
from
Centennial, CO
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously
Phase 1/2 Determination of the Dose of Recominant Human Hyaluronidase (rHuPH20) Required Enabling Up to 600 mg/kg Bodyweight of IGIV, 10% to be Administered Subcutaneously in a Single Infusion Site in Subjects With Primary Immunodeficiency (PID)
Status: Enrolling
Updated: 1/23/2018
First Allergy and Clinical Research Center
mi
from
Centennial, CO
Click here to add this to my saved trials
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously
Phase 1/2 Determination of the Dose of Recominant Human Hyaluronidase (rHuPH20) Required Enabling Up to 600 mg/kg Bodyweight of IGIV, 10% to be Administered Subcutaneously in a Single Infusion Site in Subjects With Primary Immunodeficiency (PID)
Status: Enrolling
Updated:  1/23/2018
Allergy Associates of the Palm Beaches, PA
mi
from
North Palm Beach, FL
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously
Phase 1/2 Determination of the Dose of Recominant Human Hyaluronidase (rHuPH20) Required Enabling Up to 600 mg/kg Bodyweight of IGIV, 10% to be Administered Subcutaneously in a Single Infusion Site in Subjects With Primary Immunodeficiency (PID)
Status: Enrolling
Updated: 1/23/2018
Allergy Associates of the Palm Beaches, PA
mi
from
North Palm Beach, FL
Click here to add this to my saved trials
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously
Phase 1/2 Determination of the Dose of Recominant Human Hyaluronidase (rHuPH20) Required Enabling Up to 600 mg/kg Bodyweight of IGIV, 10% to be Administered Subcutaneously in a Single Infusion Site in Subjects With Primary Immunodeficiency (PID)
Status: Enrolling
Updated:  1/23/2018
Pediatrics Allergy/Immunology Association, PA
mi
from
Dallas, TX
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously
Phase 1/2 Determination of the Dose of Recominant Human Hyaluronidase (rHuPH20) Required Enabling Up to 600 mg/kg Bodyweight of IGIV, 10% to be Administered Subcutaneously in a Single Infusion Site in Subjects With Primary Immunodeficiency (PID)
Status: Enrolling
Updated: 1/23/2018
Pediatrics Allergy/Immunology Association, PA
mi
from
Dallas, TX
Click here to add this to my saved trials
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  1/23/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 1/23/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  1/23/2018
Clinical Research Facility
mi
from
Centennial, CO
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 1/23/2018
Clinical Research Facility
mi
from
Centennial, CO
Click here to add this to my saved trials
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  1/23/2018
Clinical Research Facility
mi
from
North Palm Beach, FL
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 1/23/2018
Clinical Research Facility
mi
from
North Palm Beach, FL
Click here to add this to my saved trials
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  1/23/2018
Clinical Research Facility
mi
from
Atlanta, GA
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 1/23/2018
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  1/23/2018
Clinical Research Facility
mi
from
Durham, NC
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 1/23/2018
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  1/23/2018
Clinical Research Facility
mi
from
Cleveland, OH
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 1/23/2018
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  1/23/2018
Clinical Research Facility
mi
from
Dallas, TX
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 1/23/2018
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  1/23/2018
Clinical Research Facility
mi
from
Galveston, TX
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 1/23/2018
Clinical Research Facility
mi
from
Galveston, TX
Click here to add this to my saved trials
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  1/23/2018
Clinical Research Facility
mi
from
Milwaukee, WI
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 1/23/2018
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
UCLA CARE Center CRS (601)
mi
from
Los Angeles, CA
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
UCLA CARE Center CRS (601)
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Ucsd, Avrc Crs (701)
mi
from
San Diego, CA
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Ucsd, Avrc Crs (701)
mi
from
San Diego, CA
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Ucsf Aids Crs (801)
mi
from
San Francisco, CA
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Ucsf Aids Crs (801)
mi
from
San Francisco, CA
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
University of Colorado Hospital CRS (6101)
mi
from
Aurora, CO
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
University of Colorado Hospital CRS (6101)
mi
from
Aurora, CO
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Northwestern University CRS (2701)
mi
from
Chicago, IL
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Northwestern University CRS (2701)
mi
from
Chicago, IL
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Rush Univ. Med. Ctr. ACTG CRS (2702)
mi
from
Chicago, IL
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Rush Univ. Med. Ctr. ACTG CRS (2702)
mi
from
Chicago, IL
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Brigham and Women's Hosp. ACTG CRS (107)
mi
from
Boston, MA
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Brigham and Women's Hosp. ACTG CRS (107)
mi
from
Boston, MA
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Massachusetts General Hospital ACTG CRS (101)
mi
from
Boston, MA
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Massachusetts General Hospital ACTG CRS (101)
mi
from
Boston, MA
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Unc Aids Crs
mi
from
Chapel Hill, NC
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Unc Aids Crs
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Moses H. Cone Memorial Hospital CRS (3203)
mi
from
Greensboro, NC
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Moses H. Cone Memorial Hospital CRS (3203)
mi
from
Greensboro, NC
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Univ. of Cincinnati CRS (2401)
mi
from
Cincinnati, OH
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Univ. of Cincinnati CRS (2401)
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
The Ohio State Univ. AIDS CRS (2301)
mi
from
Columbus, OH
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
The Ohio State Univ. AIDS CRS (2301)
mi
from
Columbus, OH
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Vanderbilt Therapeutics CRS (3652)
mi
from
Nashville, TN
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Vanderbilt Therapeutics CRS (3652)
mi
from
Nashville, TN
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Houston AIDS Research Team CRS (31473)
mi
from
Houston, TX
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Houston AIDS Research Team CRS (31473)
mi
from
Houston, TX
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
31788 Alabama CRS
mi
from
Birmingham, AL
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
31788 Alabama CRS
mi
from
Birmingham, AL
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
University of Southern California (1201)
mi
from
Los Angeles, CA
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
University of Southern California (1201)
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
University of Colorado Denver ATN CRS (33022)
mi
from
Denver, CO
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
University of Colorado Denver ATN CRS (33022)
mi
from
Denver, CO
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Georgetown University CRS (GU CRS) (1008)
mi
from
Washington,
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Georgetown University CRS (GU CRS) (1008)
mi
from
Washington,
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Children's National Med. Ctr. ATN CRS (33003)
mi
from
Washington,
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Children's National Med. Ctr. ATN CRS (33003)
mi
from
Washington,
Click here to add this to my saved trials